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Abstract 
Although dysglycemia has been linked to poor clinical outcomes in hospitalized patients, 30-
50% of inpatients continue to have out-of-range glucose values. The use of clinical decision 
support software to manage intravenous insulin infusions has been well established, but the 
clinical impact of the ongoing updates and modifications to the proprietary algorithms are not 
always clear. The purpose of this Doctor of Nursing project was to evaluate a software update 
implementing a clinical decision support software stability requirement and the effects on blood 
glucose control in hospitalized diabetic and hyperglycemic adult patients following 
discontinuation of an intravenous insulin regimen. A retrospective analysis of a before and after 
cohort evaluated the number of patient days with (a) a mean blood glucose value within the 
range of 70-180 mg/dL, (b) a blood glucose <40 mg/dL, (c) a blood glucose <70 mg/dL, (d) a 
blood glucose >180 mg/dL and (e) a blood glucose level >300 mg/dL in patients requiring 
intravenous insulin during the day of transition and up to three days following discontinuation of 
intravenous insulin in both a provider discretion cohort (pre-intervention) and a stability 
requirement cohort (post-intervention). The final data profile resulted in 103 individual patients 
for the provider discretion cohort and 104 for the stability requirement cohort, with a total 
n=207. The intervention did not significantly impact glycemic outcomes or clinical process 
outcomes, except for decreasing variation in provider utilization of transition orders based on 
pre-admission diabetes control. The results of this study demonstrate the importance of 
evaluating software updates prior to widespread implementation and beg the question of whether 
that responsibility should fall on the software creators or the implementation sites.  
 Keywords: diabetes mellitus, hyperglycemia, hypoglycemia, clinical decision support 
software, insulin dosing, blood glucose control, stability requirement 
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The Effects of a Clinical Decision Support Software Program Stability Requirement on 
Glycemic Outcomes 
Diabetes mellitus is a chronic disease currently affecting 9.3% of Americans, and the 
Center for Disease Control and Prevention (2014) has projected that if current trends continue, 
one in three Americans will suffer from diabetes by 2050. Within the inpatient setting, 
approximately 25-30% of adult and critical care units are comprised of patients with a diagnosis 
of diabetes (Draznin, Gilden, Golden, & Inzucchi, 2013). Over the last decade, the increase in 
prevalence and impact of glycemia on long-term outcomes has placed attention on inpatient 
glycemic management (ACE/ADA Task Force on Inpatient Diabetes, 2006). The American 
Association of Clinical Endocrinology (AACE) and the American Diabetes Association (ADA) 
have published extensive guidelines on the proper management of inpatient glycemia, which has 
led to tremendous efforts by hospitals and administrations across the country to improve patient 
care (Lowell R. Schmeltz, 2011). 
In 2012, the estimated national cost of diabetes in the United States was $245 billion 
(American Diabetes Association, 2013). Of the $245 billion, the largest contributor, composing 
43%, was inpatient hospital care related to higher admission rates and longer lengths of stay per 
admission for people with diabetes (American Diabetes Association, 2013). The annual per 
capita health care expenditure for people with diabetes was 2.3 times higher than for those 
without diabetes (American Diabetes Association, 2013).  
The intersection of quality and economics can also be seen in the Joint Commission’s 
disease specific certification for inpatient diabetes management. The aims of this certification 
include coordination of chronic care, early detection, preventive measures, and reduction of 
overall healthcare costs (Braithwaite et al., 2008). This certification is based on compliance with 
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the national standards of care and promotes performance measurement and improvement projects 
within the realm of inpatient diabetes care (Braithwaite et al., 2008). Disease-specific 
certifications are increasing in importance to providers, patients, and healthcare institutions 
because of the commitment to quality and patient safety that is demonstrated with the attainment 
and maintenance of certification (Braithwaite et al., 2008).   
The project site facility is a 504-bed, full-service community hospital located in a 
suburban, midwestern city and part of a 46-hospital multistate healthcare system. The inpatient 
diabetes program at this hospital serves adults of all ethnicities and cultural heritages. Additional 
vulnerable populations present in this hospital setting include pregnant women, elderly, 
homeless, illiterate, mentally ill, and economically and educationally disadvantaged individuals. 
The 2010 census data indicates population by race: White alone (86.34%), Black or African 
American alone (5.30%), Asian alone (3.05%), American Indian and Alaska native alone 
(0.39%) and Native Hawaiian and other Pacific native alone (0.08%; U.S. Census Bureau, 2012). 
Population by Hispanic or Latino origin - of any race - indicates 7.48% (U.S. Census Bureau, 
2012).  
Problem 
Although research and national evidence-based practice guidelines support the negative 
impact of dysglycemia on patient morbidity and mortality, significant barriers are encountered in 
obtaining proper glycemic control within the inpatient setting. It is reported that 30-50% of adult 
inpatients have hyperglycemia during their hospital admission (Draznin, Gilden, Golden, 
&Inzucchi, 2013).  The standard of care for glycemic management of critically ill individuals 
includes the use of intravenous insulin infusions which can accommodate the complex medical 
status and numerous variables impacting this patient population (American Diabetes Association, 
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2016).  The use of clinical decision support software (CDSS) programs have been found to be 
safe and effective in the dosing of intravenous insulin and are widely implemented in hospitals 
throughout the country and the world (American Diabetes Association, 2016; Mann, Jones, 
Wolf, & Wade, 2011; Van Herpe et al., 2013). The purpose of this Doctor of Nursing project was 
to evaluate a software update implementing a CDSS stability requirement and the effects on 
blood glucose control in hospitalized diabetic and hyperglycemic adult patients following 
discontinuation of an intravenous insulin regimen.  
Facilitators of this project included the multi-state 46-hospital health care system and the 
hospital administrators of the project site facility. A task force created by the health care system 
and composed of representatives from numerous hospitals throughout the system was actively 
evaluating the CDSS utilized by the healthcare system when this project was proposed by the 
student investigator in order to better understand the clinical impact of the software updates.  The 
most significant barrier was that the CDSS only allows for analysis of glycemic data while a 
patient is on intravenous insulin. A substantial amount of time and manual data collection was 
needed to evaluate the glycemic data of these individuals following their transition from 
intravenous insulin to subcutaneous insulin.  
The sustainability of this program is probable due to the results of this study and 
continued implementation by the program creators and the site facility. From a cost-savings 
perspective, dysglycemia during hospital admission has been shown  to be correlated with higher 
charges, longer lengths of stay and higher morbidity and mortality rates (Curkendall, et al., 2009; 
Gandhi, Nuttall, Abel, Mullany, & al, 2005; Moghissi et al., 2009; Van den Berghe et al., 2001, 
2006). The national hospital adjusted expense per patient is estimated at $2,212 per patient day, 
indicating that increased hospital length of stay can cost the patient and the health care system 
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additional expense (Curkendall, et al., 2009; Health Forum, LLC, 2015; L. R Schmeltz, 2011; 
See Appendix A for Logic Model).                               
Review of the Evidence 
The aim of this study was to investigate the following question: In hospitalized diabetic 
and hyperglycemic adult patients requiring intravenous insulin, did the implementation of a 
stability requirement to an intravenous insulin dosing clinical decision support software 
compared to patients transitioned off of intravenous insulin under provider discretion affect the 
number of patient days with (a) a mean blood glucose value within the range of 70-180 mg/dL, 
(b) a blood glucose <40 mg/dL, (c) a blood glucose <70 mg/dL (d) a blood glucose level >180 
mg/dL, and (e) a blood glucose level >300 mg/dL during the day of transition and up to three 
days following discontinuation of intravenous insulin during a three-month timeframe prior to 
and following implementation of a software update at the site facility?  
Secondary questions included the following: (a) Did provider utilization of the CDSS 
transition orders differ by cohort? (b) Did the hospital length of stay differ by cohort? (c) Was 
there a relationship between hemoglobin A1c for individuals with or without transition orders by 
cohort? And (d) Was there an interaction between use of transition orders and cohort when 
measuring patient days requiring intravenous insulin?  
To determine the existing evidence related to inpatient glycemic management and 
computerized insulin dosing software, a review of the literature was conducted using the 
following databases: Cumulative Index to Nursing and Allied Health Literature (CINAHL), 
EBSCOhost Databases, MEDLINE (Ovid), Medline Plus, Cochrane, and Proquest Nursing and 
Allied Health Source. Search terms used were diabetes mellitus, blood glucose, hyperglycemia, 
hypoglycemia, clinical decision support software, intravenous insulin dosing, subcutaneous 
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insulin dosing, transition and stability requirement. A total of 30 studies were selected including 
four evidence-based practice guidelines, one systematic review, 15 quantitative studies, one 
qualitative study, and nine editorials/reports. Organized by a rating system for the hierarchy of 
evidence (see Appendix B), five Level I studies, six Level II studies, three Level III studies, six 
Level IV studies, one Level VI study, and nine Level VII studies were identified (Melnyk & 
Fineout-Overholt, 2015).  
Dysglycemia and the Effects on Clinical Outcomes 
 Inpatient glycemic management has been brought to the forefront of inpatient care over 
the last 15 years due to the recognition that glucose control, even for a short time during an 
inpatient admission, can have a substantial impact on patient outcomes. The publication of 
interventional studies showing improved outcomes for patients with better glucose control 
experiencing myocardial infarction, cardiac surgical procedures, infection and critical illnesses 
has forced healthcare to make substantial strides towards improving glycemic outcomes 
(ACE/ADA Task Force on Inpatient Diabetes, 2006; Baker et al., 2006; Gandhi et al., 2005; Van 
den Berghe et al., 2001). Not only is hyperglycemia an independent risk factor for inpatient 
mortality, but also the degree of hyperglycemia is associated with increased risk of adverse 
outcomes. The higher the blood glucose level, the higher the relative risk (Baker et al., 2006; 
Prieto-Sanchez, 2011). Improved glucose control in both medical and surgical patients has been 
shown to result in lower rates of hospital complications such as sternal wound infections, sepsis, 
stroke, coma, acute renal failure, new-onset atrial fibrillation, cardiac arrest, prolonged 
ventilation, pneumonia, and death (American Diabetes Association, 2016; Gandhi et al., 2005; 
Moghissi et al., 2009; Umpierrez et al., 2012). 
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 While the effects of hyperglycemia on clinical outcomes may be more recent, the 
identification of severe hypoglycemia (blood glucose <40 mg/dL) as an independent risk factor 
for mortality is not new (Curkendall et al., 2009; Moghissi et al., 2009). Hypoglycemia can 
contribute to cardiac arrhythmias, seizures, brain damage and death (Prieto-Sanchez, 2011). The 
counter regulatory response to hypoglycemia places a substantial amount of stress on the body 
and is associated with increased adverse outcomes (American Diabetes Association, 2016; 
Moghissi et al., 2009). 
Inpatient Glycemic Goals and Treatments 
The evidence-based practice guidelines for inpatient glycemic management focus on the 
importance of maintaining normoglycemia while avoiding both hyperglycemia and 
hypoglycemia. There has also been contradictory research published on the benefits of strict 
glycemic control (Griesdale et al., 2009; NICE-SUGAR Study Investigators, 2009; Van den 
Berghe et al., 2001, 2006). Initially, the recommendation for critical ill patients was to keep the 
blood glucose as close to 110 mg/dL as possible and for non-critically ill patients the 
recommendation was 90-130 mg/dL (American Diabetes Association, 2005). After the 
publication of a large, international randomized trial indicating that patients in the intensive 
treatment group (target blood glucose of 81-108 mg/dL) had increased mortality when compared 
to those with a target blood glucose of 180 mg/dl or less, the national guidelines subsequently 
loosened the target blood sugar goals and focused on avoiding hypoglycemia while maintaining 
adequate glycemic control (Moghissi et al., 2009; NICE-SUGAR Study Investigators, 2009; 
Umpierrez et al., 2012). Currently, a glucose target between 140-180 mg/dL is recommended for 
most critically and non-critically ill patients, while recognizing that some patients who are 
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clinically stable may be appropriate for glucose targets <140 mg/dL (American Diabetes 
Association, 2016).  
Current clinical practice guidelines recommend the use of intravenous insulin for 
glycemic management of the critically ill patient population (American Diabetes Association, 
2016; Moghissi et al., 2009; Qureshi, Deakins, & Reynolds, 2012; Umpierrez et al., 2012). The 
advantage of utilizing intravenous insulin is related to the ability to titrate the infusion frequently 
and safely in the presence of significant variables impacting glucose levels of severely ill 
individuals. Within the acute care - non-critical care - setting, the treatment of diabetes and 
hyperglycemia should be managed with a subcutaneous multi-modal insulin regimen (see 
Appendix C) as oral hypoglycemia medications are not recommended for the majority of 
hospitalized patients (American Diabetes Association, 2016; Moghissi et al., 2009; Umpierrez et 
al., 2012). As an individual’s acuity and illness improve, it is necessary to transition from an 
intravenous insulin infusion to a subcutaneous insulin regimen.  
Barriers to Obtaining Optimal Glycemic Control Following Transition  
The delicate balance of avoiding dysglycemia can be extremely difficult to achieve in a 
setting with a number of variables including unanticipated changes in nutrition, medication 
changes, the use of medications associated with increased insulin resistance, complicating 
comorbidities, and organizational barriers (Moghissi et al., 2009). The transition of patients from 
an intravenous insulin infusion to a multimodal subcutaneous insulin regimen has been 
associated with inadequate glycemic control and is often complicated by the patients’ acuity and 
nutritional intake (Avanzini et al., 2011; Kreider & Lien, 2015). Other identified factors 
inhibiting optimal control include clinical inertia and knowledge deficits among providers 
regarding the management of inpatient glycemia (Braithwaite et al., 2008; Draznin et al., 2013; 
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Prieto-Sanchez, 2011; Ross et al., 2012). Specifically, problems that have been identified 
following transition from intravenous to subcutaneous insulin regimens often include 
discontinuing the infusion when it is not yet safe or rather at a safe time but logistical errors 
occur such as provider uncertainty surrounding the dosage calculations and distributions required 
to adequately address insulin requirements when transitioning (Kreider & Lien, 2015; Qureshi et 
al., 2012). A subsequent barrier inhibiting optimal transitions is the lack of adequate time for the 
subcutaneous regimen to overlap with the intravenous regimen; the Endocrine Society currently 
recommends at least one to two hours of overlap (Qureshi et al., 2012; Umpierrez et al., 2012).  
Following transition, proper implementation of a multi-modal subcutaneous insulin 
regimen requires frequent review and revision of the regimen based on glycemic outcomes, and 
can be a time-intensive process (Prieto-Sanchez, 2011). Recognized solutions currently seen in 
practice across the country include the use of inpatient diabetes specialists, administrative 
support of interdisciplinary quality improvement committees, order sets promoting the use of 
scheduled insulin, insulin algorithms, and provider/staff education (Draznin et al., 2013; Ross et 
al., 2012; Lowell R. Schmeltz, 2011; Umpierrez et al., 2012). Although significant national 
initiatives exist to incorporate these standards of care into daily practice, 30-50% of adult 
inpatients do not demonstrate good glycemic control during their inpatient hospital stay (Draznin 
et al., 2013).  
Clinical Insulin Dosing Software Programs 
 Intravenous insulin infusions directed by CDSS programs have become well established 
in critical-care settings across the country and are supported in the national guidelines for 
inpatient diabetes management (American Diabetes Association, 2016; Kalfon et al., 2014; 
Mader et al., 2014; Mann et al., 2011; Neubauer et al., 2015; Van Herpe et al., 2013). Computer 
EFFECTS ON GLYCEMIC OUTCOMES 11 
driven programs have been shown to have better glycemic control and fewer out of range 
glucose results than paper-based protocols in a prospective cohort analysis (Saur, Kongable, 
Holewinski, O’Brien, & Nasraway, 2013). The CDSS utilized by the site-facility was cited in 
two articles that indicated the program was effective in managing hyperglycemia with less 
variability and no increase in hyperglycemia (Cochran et al., 2006; Igneri et al., 2016). Both 
were retrospective reviews in the critical care setting evaluating only glucose management on 
intravenous insulin regimens. While no studies were found evaluating a CDSS stability 
requirement, predictors of poor transition outcomes included wide blood glucose fluctuations and 
high variability of blood glucose levels and insulin infusion rates (Kreider & Lien, 2015). A 
substantial amount of the literature pertaining to transition from intravenous to subcutaneous 
insulin depicts the different algorithms and options for dosing insulin when transitioning patients 
to subcutaneous insulin. These were not considered relevant to this project as both cohorts for 
this project were transitioned based on the CDSS’s proprietary algorithm.  
Theory 
Imogene King’s Theory of Goal Attainment originated from a conceptual system 
incorporating three interacting systems: personal, interpersonal, and social (Butts & Rich, 2015; 
Messmer, 2006). Due to the ever-changing field of healthcare practice in response to 
technological and research advances, healthcare teams need interpersonal skills and knowledge 
to adapt to the constantly changing environment (King, 2007). King has identified four concepts 
that compose the transaction process: perception, communication, interaction, and transaction 
(King, 2007). This framework provides a theoretical basis on which the nursing process is built, 
and the effectiveness of nursing care is based on outcome goals (Butts & Rich, 2015; King, 
2007). The Theory to Application Diagram (see Appendix D) shows King’s Model of 
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Transactions applied to the implementation of a CDSS stability requirement. From a broader 
perspective, King’s transaction process facilitates establishing goals for evaluating quality care 
and evidence based practice in the healthcare environment that is constantly being forced to 
change in response to technological advances (King, 2007).  
Methods  
The site facility does not have an Institutional Review Board, thus human subjects 
determination was established by the University of Missouri-Kansas City IRB (see Appendix E 
for IRB Approval Letter). The student investigator has no employment or financial affiliation 
with the developer of the CDSS; the student investigator is employed by the site facility.  
Setting and Participants 
The setting for this project was a 504-bed community hospital located in the Midwest and 
part of a 46-hospital multistate healthcare system. The CDSS underwent an update in April of 
2015, at which time an addition of a stability requirement was made which must be met by each 
patient before the provider can access the programs’ dosing algorithm for transition to 
subcutaneous insulin. Thus, a single-center, retrospective analysis was conducted of a before and 
after cohort including adult, hospitalized patients requiring a continuous insulin infusion between 
the dates of Jan 1, 2015 – March 31, 2015 (provider discretion cohort) and May 1, 2015 – July 
31, 2015 (stability requirement cohort). 
A report generated by the hospital’s corporate clinical effectiveness team was used to 
identify adult, hospitalized individuals requiring intravenous insulin during the pre-determined 
time frames before and after the program update. Patients were excluded if they did not receive a 
minimum of 12 hours of intravenous insulin dosing and if they did not have a minimum of one 
patient day on subcutaneous insulin following transition off intravenous insulin. Data was 
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collected and stored under a generic identification number which could not be associated with 
participants protected health information. There was no ability to link the data back to the subject 
after the data was entered. The data was stored on the health system’s secure sever that complies 
with the Health Insurance Portability Accountability Act.  
For each patient day that data was available, the following information was collected: 
type of insulin regimen, average blood sugar level, if the average blood sugar was within range 
of 70-180 mg/dL, if a blood sugar of <40 mg/dL occurred during that patient day, if a blood 
sugar of <70 mg/dL occurred during that patient day, if a blood sugar of >180 mg/dL occurred 
during that patient day, and if a blood sugar of >300 mg/dL occurred that patient day. Patient 
demographic and diagnostic data including age, sex, type of diabetes, serum creatinine at 
admission, hemoglobin A1c, body mass index, hospital length of stay in days, hospital days with 
intravenous (IV) insulin, and presence of diabetic ketoacidosis or hyperosmolar hyperglycemia 
syndrome on admission were collected. For each individual, it was noted whether or not the 
CDSS transition order for subcutaneous insulin dosing was utilized by the provider (see 
Appendix F for Data Collection Template).  
Evidence Based Practice Intervention 
Intravenous insulin dosing computerized decision support software programs operate on 
proprietary algorithms that require data to be uploaded via interphase or manually entered by the 
clinician. The site facility utilized the same CDSS since 2009 in the emergency department, 
intensive care unit, and cardiac care unit. The update that occurred on April 7, 2015 changed the 
software from a local workstation to a cloud-based program, allowing clinicians easier access to 
the program directly from the electronic medical record. In addition to the change in how the 
program was accessed and the visual display of the program, there were updates to the predictive 
EFFECTS ON GLYCEMIC OUTCOMES 14 
algorithm including estimated residual extracellular insulin (EREI), diabetic ketoacidosis (DKA) 
status, and hyperosmolar hyperglycemia syndrome (HHS) status. The EREI uses information 
based on the change in blood sugar and kidney function to estimate insulin that may still be on 
board to prevent hypoglycemia. The program also makes a recommendation for recovery 
carbohydrate if indicated. The addition of the DKA and HHS status allowed for goal ranges 
based on the status chosen. Unless otherwise specified, the goal range was 100-140 mg/dL. If the 
patient was put into the DKA status, the goal range was 150-200 mg/dL. For HHS, the goal 
range was 200-250 mg/dL. Once specific criteria had been met (resolution of DKA/HHS), the 
patient was transitioned into the standard mode of therapy and a goal range of 100-140 mg/dL. 
These changes impacted the predictive dosing model, while the patient was on intravenous 
insulin, and were not evaluated as part of this project. 
                The April 2015 update also included the addition of a stability requirement for 
providers to access the subcutaneous transition orders. Prior to this update, the provider was able 
to access the transition orders at any point in time when they considered the patient’s medical 
status and blood glucose was appropriate for transition. This decision, based on provider 
discretion, required the provider to analyze many variables including, but not limited to, the 
hemodynamic and metabolic state of the patient, intravenous insulin requirements to maintain 
optimal blood sugar control, whether the patient was able to tolerate oral intake or not, and other 
comorbidities and treatments that could have impacted glucose control. Once the provider 
decided to transition the patient to subcutaneous insulin, they could access the transition orders 
generated by the CDSS. The proprietary algorithm would then determine the subcutaneous 
insulin regimen based on the patients’ nutritional intake and intravenous insulin requirement. 
These orders were entered into the electronic medical record by the pharmacist, and the patient 
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would be transitioned from intravenous to subcutaneous insulin. The facility policy requires 
patients receive a dose of basal insulin three hours prior to discontinuation of the insulin infusion 
to avoid rebound hyperglycemia. 
                The stability requirement that was added no longer allowed the provider to access the 
transition orders at any point in time, but rather only after the CDSS deemed the patient stable 
based on several factors built into the algorithm. These factors required that the patient have a 
mean blood glucose <140 mg/dL and a blood glucose variability <25. The program would mark 
the patient as “Stable” and then the transition orders could be selected and generated. Prior the 
patient being “Stable”, the transition orders would be dithered out (See Appendix G for 
Intervention Explanation). The purpose of the stability requirement was to only allow providers 
to access the CDSS’s generated orders during appropriate times when enough data was available 
and the blood glucose was stable enough for accurate subcutaneous dosing to be calculated. 
Following implementation of the update, there was concern voiced by clinicians that it could 
cause a delay in transition because of difficulty attaining stability that could result in possible 
increase in time required on intravenous insulin and ultimately hospital length of stay. The 
primary barrier reported by clinicians to achieving criteria for stability was post-prandial blood 
glucose excursions in patients who ate while on intravenous insulin. Oral intake is generally 
considered a sign of improving medical status, but can make glycemic control challenging on 
intravenous insulin regimens. 
Change Theory and Evidence Based Practice Model 
Due to uncertainty surrounding the program update and questions regarding the necessity 
and benefit of the CDSS stability requirement, Kotter and Cohen’s Model of Change was chosen 
as the change theory for this project. This model relies on appealing to one’s emotion for 
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achieving behavior change and emphasizes that individuals are more likely to change when their 
feelings are influenced by truths than when merely given facts meant to affect their way of 
thinking (Melnyk & Fineout-Overholt, 2015). This model embraces an 8-step process that was 
recently updated in 2014 from the original model in 1996 to include the following: 1) create 
sense of urgency 2) build a guiding coalition 3) form a strategic vision and initiatives 4) enlist a 
volunteer army 5) enable action by removing barriers 6) generate short-term wins 7) sustain 
acceleration, and 8) institute change (Kotter International, 2016).  
Marita Titler’s Iowa Model of Evidence Based Practice was the evidence-based practice 
model applied to this project (Titler, 2007). The Iowa model relies on both problem focused and 
knowledge based triggers to lead healthcare providers towards improved quality of care (Melnyk 
& Fineout-Overholt, 2015). After considering clinical application and organizational priorities, a 
team is formed, the relevant research and literature is critiqued, the practice change is piloted, 
and if appropriate, the practice change is integrated into general practice (Melnyk & Fineout-
Overholt, 2015). Throughout the process, there are feedback loops in place to direct decision-
making. This feedback loop is imperative for continued sustainability of the intervention and 
long-term maintenance of change.  
Study Design and Validity 
After receiving a Not Human Subjects Determination, a single-center, retrospective 
analysis was conducted of a before and after cohort including adult, hospitalized patients 
requiring a continuous insulin infusion between the dates of Jan 1, 2015 – March 31, 2015 
(provider discretion cohort) and May 1, 2015 – July 31, 2015 (stability requirement cohort). 
The participants included individuals admitted to the intensive care unit and the 
cardiovascular care unit at the site facility. Patients requiring intravenous insulin must be 
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admitted to one of these two units due to nursing training on the CDSS based on the site 
facility’s policy.  
Internal validity of this project could be threatened by the retrospective, observational 
nature of the study with a lack of randomization. Due to the before and after cohort design, there 
would be the possibility of extraneous variables impacting glucose control. Some examples 
include heightened awareness related to provider and staff education surrounding the 
intervention, additional ongoing process improvement projects at the site facility, variations in 
providers and nursing staff, and a patient population that is always changing. Also, the quality 
and consistency of provider and staff education related to glucose management and their 
familiarity with technology could impact the validity of the study.   
The intervention may only be applicable to other intensive care and cardiac care units. 
External validity is strengthened by evaluating both a critical care and acute care nursing unit 
that incorporates a wide variety of patient acuity levels and diagnoses (See Appendix H for 
Project Timeline Flow Graphic and Appendix I for Intervention Flow Diagram).  
Outcomes and Measurement Instruments 
Primary outcomes for this project include measurement of glycemic outcomes for the 
provider discretion cohort and the stability requirement cohort. Glycemic outcomes evaluated by 
cohort include the following: the number of patient days with (a) a mean blood glucose value 
within the range of 70-180 mg/dL, (b) a blood glucose <40 mg/dL, (c) a blood glucose <70 
mg/dL, (d) a blood glucose >180 mg/dL, and (e) a blood glucose level >300 mg/dL in patients 
requiring intravenous insulin during the day of transition and up to three days following 
discontinuation of intravenous insulin. Secondary outcomes include provider utilization of the 
CDSS transition orders by cohort, hospital length of stay by cohort, the relationship between 
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hemoglobin A1c and utilization of transition orders by cohort, and patient days requiring IV 
insulin by cohort.  
A recent study supported the use of mean blood glucose as a simple, accurate form of 
glycemic measurement during the inpatient stay, as well as powerful predictor of in-hospital 
mortality (Kosiborod et al., 2008). Mean blood glucose is the average of a patient’s glucose level 
over time. Based on clinical practice guidelines, the recommended range for a random blood 
glucose is 70-180 mg/dL (Umpierrez et al., 2012). In the pursuit of decreasing hyperglycemia, it 
is imperative that hypoglycemia is not inadvertently increased due to the morbidity and mortality 
associated with hypoglycemia (Prieto-Sanchez, 2011; Umpierrez et al., 2012).  Therefore, this 
project measured two different hypoglycemia outcomes: blood glucose <40 mg/dL and blood 
glucose < 70 mg/dL. A commonly utilized metric in the inpatient setting is the patient-day unit; 
there is support for the use of this metric in the assessment of hypoglycemic events (Goldberg et 
al., 2006). A severe hypoglycemic event is defined as a blood glucose <40 mg/dL and a 
hypoglycemic event is defined as a blood glucose <70 mg/dL (American Diabetes Association, 
2016). Both values are being measured independently due to the increased morbidity associated 
with severe hypoglycemia (Moghissi et al., 2009). The percent of patient days with a blood 
glucose >180 mg/dl and >300 mg/dL were also evaluated as two of the primary outcomes. These 
outcomes evaluated for hyperglycemia and severe hyperglycemia that may not be fully 
recognized by a mean blood glucose alone.  
While arterial and venous blood glucose samples have been established to have high 
reliability and validity, there has been concern related to the accuracy of point-of-care blood 
glucose meters (Nichols, 2011). Errors in blood glucose meter results can stem from patient or 
methodology inferences, such as: low hematocrit, decrease peripheral perfusion and/or certain 
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medications including ascorbic acid, maltose, and galactose (Lou & Robinson, 2010; Nichols, 
2011). Due to the high number of personnel using glucose meters throughout the inpatient 
hospital setting, there are also a variety of errors that can result from operator error. A few 
possibilities include expired reagents, incorrect disinfection, failure to analyze controls, and 
incorrect patient identification (Nichols, 2011).  
The pilot site facility utilized the Nova Biomedical StatStrip glucose meters. As of 2014, 
this meter was utilized by 53% of all hospitals in the United States and has been designed to 
eliminate the effects of abnormal hematocrit, ascorbic acid, uric acid, acetaminophen, bilirubin, 
maltose, galactose, and oxygen  (Nova Biomedical, 2014). There have been 138 studies 
evaluating analytical performance of the Nova StatsStrip glucose meter between 2007 and 2014, 
and the sensor technology has been shown to improve accuracy when compared to numerous 
other glucose meters (Lou & Robinson, 2010; Nova Biomedical, 2014). To minimize user error, 
the site facility policy required that new staff receive orientation and validate proper use of the 
meter upon hire followed by annual competency for all associates. The site facility policy 
required staff to use venous or arterial samples when a patient was deemed inappropriate for 
capillary sampling. Some examples of patients who are inappropriate for capillary sampling 
include critically ill patients who were hemodynamically unstable and/or had decreased 
peripheral perfusion (Inoue, Egi, Kotani, & Morita, 2013).  
Quality of Data and Analysis Plan  
Cohort groups were compared for initial demographic equality. The Independent t-test 
was used to compare continuous variables (hospital length of stay in days, age, serum creatinine 
at admission, hemoglobin A1c, body mass index, and hospital days with IV insulin). Categorical 
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variables (sex, diabetes status and history of DKA or HHS) were compared using the chi square 
test of association.  
All continuous data is presented as mean +/- standard deviation. All categorical data is 
presented as numeric counts of percentages. Primary outcomes data were analyzed using the chi 
square test of association. The secondary outcome regarding the use of transition orders by 
provider was analyzed using the chi square test of association. The influence of cohort group on 
hospital length of stay was assessed using an independent t-test. A 2x2 factorial independent 
analysis of variance was employed to assess the relationship between hemoglobin A1c for 
individuals with or without transition orders by cohort group. Finally, a 2-way ANOVA was 
used to assess whether there was significant interaction between the use of transition orders and 
cohort when measuring patient days spent in the hospital with IV insulin. Data analysis was 
completed using SPSS v24.  
Results 
Setting and Participants 
The setting for this project was a 504-bed community hospital located in a suburban, 
midwestern city and part of a 46-hospital multistate healthcare system. This single-center 
retrospective analysis was conducted on a before and after cohort including adult hospitalized 
patients requiring a continuous insulin infusion between the dates of Jan 1, 2015 – March 31, 
2015 (provider discretion cohort) and May 1, 2015 – July 31, 2015 (stability requirement 
cohort). Patients were excluded if they were on intravenous insulin for less than 12 hours or if 
there was not at least one patient day of glucose data while on a subcutaneous insulin regimen 
post-transition. 
Intervention Course 
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  Following receipt of IRB Approval for Not Human Subjects Determination on January 
31, 2017 (See Appendix E for IRB Approval Letter), the student investigator obtained reports 
from the organization’s clinical effectiveness office that identified patients requiring intravenous 
insulin between January 1, 2015 – March 31, 2015 and May 1, 2015 – July 31, 2015 at the site 
facility. These reports also contained the primary glycemic outcomes by patient day. The data 
was transcribed from the report to the excel data collection sheet. In addition, the demographic 
and diagnostic data was collected from the electronic medical record at the same time and 
entered into the excel data collection sheet. All information on the excel data collection sheet 
was de-identified with no ability to link information back to the patient and all data collection 
was performed on the site-facility’s secure network. The data was then transcribed and uploaded 
to SPSS software for statistical analysis.  
Outcome Data 
The final data profile resulted in 103 individual patients for the provider discretion cohort 
and 104 for the stability requirement cohort, with a total n=207. Individuals in which the 
provider utilized the transition orders totaled n=128, 71 in the provider discretion cohort and 56 
in the stability requirement cohort. The data indicates that the cohorts were well matched with no 
significant differences in demographics or diagnostics. 
 The provider discretion cohort participants were 54% male and 46% female. Seventeen 
percent had no history of diabetes, 17% had a history of Type 1 Diabetes, and 67% had a history 
of Type 2 diabetes.  Sixty-two percent of participants did not have DKA or HHS documented 
during the admission; 36% had DKA and 2% had HHS documented. The stability requirement 
cohort participants were 50% male and 50% female. Sixteen percent had no history of diabetes, 
25% had a history of Type 1 Diabetes, and 59% had a history of Type 2 Diabetes. Sixty-two 
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percent of participants in the stability requirement cohort did not have DKA or HHS documented 
during the admission; 35% had DKA and 3% had HHS documented.  
For the data collected on the day of transition from intravenous to subcutaneous insulin 
for individuals in which the transition orders were utilized each cohort was analyzed using the 
chi square test of association for differences in the number of days that the average blood sugar 
was within range of 70-180 mg/dL, the number of days that the patient experienced a blood 
sugar <40 mg/dL, <70 mg/dL, >180 mg/dL, and >300 mg/dL. There was no significant 
difference between the provider discretion cohort and the stability requirement cohort in 
individuals in which the transition orders were utilized on the day of transition for average blood 
glucose within range of 70-180 mg/dL (X21 = 1.451; p = .228), the number of days that the 
patient experienced a blood glucose <40 mg/dL (X21 = 2.032; p = .154), <70 mg/dL (X
2
1 = 1.021; 
p = .312), >180 mg/dL (X21 = 1.205; p = .272), and >300 mg/dL (X
2
1 = 1.951; p = .163).  
Using the chi square test of association for individuals in which transition orders were 
utilized, the average blood sugar within range of 70-180 mg/dL, the number of days that the 
patient experienced a blood sugar <40 mg/dL, <70 mg/dL, >180 mg/dL, and >300 mg/dL were 
evaluated for day one, day two, and day three of subcutaneous insulin regimen following 
discontinuation of intravenous insulin. There was no significant difference between the provider 
discretion cohort and the stability requirement cohort in individuals in which transition orders 
were utilized on the first day of subcutaneous insulin for average blood glucose within range of 
70-180 mg/dL (X21 = 2.360; p =.124), the number of days that the patient experienced a blood 
glucose <40 mg/dL (X21 = 1.772; p =.183), <70 mg/dL (X
2
1 = 1.090; p = .296), >180 mg/dL (X
2
1 
= .319; p =.572), and >300 mg/dL (X21 = .009; p = .924). There was no significant difference 
between the provider discretion cohort and the stability requirement cohort in individuals in 
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which transition orders were utilized on the second day of subcutaneous insulin for average 
blood glucose within range of 70-180 mg/dL (X21 = .062; p = .803), the number of days that the 
patient experienced a blood glucose <40 mg/dL (X21 = 2.979; p = .084), <70 mg/dL (X
2
1 = 2.085; 
p = .149), >180 mg/dL (X21 = .007; p = .932), and >300 mg/dL (X
2
1 = .132; p = .716). There was 
no significant difference between the provider discretion cohort and the stability requirement 
cohort in individuals in which transition orders were utilized on the third day of subcutaneous 
insulin for average blood glucose within range of 70-180 mg/dL (X21 = .029; p = .865), the 
number of days that the patient experienced a blood glucose <40 mg/dL (X21 = 2.119; p = .145), 
<70 mg/dL (X21 = 2.119; p = .145), >180 mg/dL (X
2
1 = .047; p = .829), and >300 mg/dL (X
2
1 = 
.053; p = .818). 
The secondary question of whether provider utilization of the CDSS transition orders 
differed by cohort was analyzed using the chi square test of association. There was not a 
significant difference between cohorts in the number of individuals that the providers choose to 
use the CDSS transition orders (X21 = 4.375; P=.036). The influence of cohort group on hospital 
length of stay (LOS) was assessed using an independent t-test. LOS in days was 7.27 +/- 5.412 
days for the patients in the provider discretion group and 6.67 +/- 4.501 days for the patients in 
the stability requirement group.  The mean difference in LOS between cohort groups was .601 
days.  This was found to be not statistically significantly different (t(126) = .679; P = .503).  It can 
be said that cohort group assignment did not significantly influence LOS.  
A 2x2 factorial independent analysis of variance was employed to assess the relationship 
between hemoglobin A1c for individuals with or without transition orders by cohort group. In 
the provider discretion cohort, there was a significant difference in the mean A1c for individuals 
in which the provider chose to utilize the CDSS transition orders and those that they did not. The 
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mean A1c was 1.586% higher (P = .002) for individuals that had transition orders used in the 
provider discretion cohort. In comparison, there was no statistical difference between the mean 
A1c for individuals in the stability requirement cohort that had transition orders utilized versus 
those that did not (mean difference = .061; P = .898).  
A 2-way ANOVA was used to assess whether there was significant interaction between 
the use of transition orders and cohort when measuring patient days spent in the hospital with IV 
insulin. The interaction between cohort and the writing of transition orders was found to be not 
statistically significant. With this, one should look at both contributing variables individually. It 
was found that the cohort group did not influence the number of days the patient spent in the 
hospital in IV insulin (F(1.203) = 1.83; p = .178). Also, whether or not transition orders were 
written did not influence the number of days in the hospital on IV insulin (F(1,203) = .025; p = 
.876; See Appendix J for Statistical Analysis). 
Discussion 
Successes 
 The most important success of this study was the evaluation of a CDSS stability 
requirement that has not previously been researched. While glycemic outcomes did not change 
significantly between the provider discretion and the stability requirement cohort, there was     
not a significant increase in the length of time patients were required to be on intravenous 
insulin, an increase in the hospital length of stay, or a reduction in the provider’s utilization of 
the transition orders. Thus, the software update did not appear to have a clinically significant 
impact on glycemic outcomes or clinical process outcomes.  
Study Strengths 
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 Strengths of this study included the site facility, a culture supportive of research, and the 
provision of resources by leadership. This 504-bed community hospital supports a broad range of 
patients from the Kansas City metro area and the use of intravenous insulin in both the intensive 
care unit and the cardiac care unit facilitated a large range of patient acuity levels. Also, this 
facility has several variables encouraging a culture that supports inpatient glycemic management 
such as monthly evaluation by the health system’s leadership regarding nine different glycemic 
outcomes for the entire hospital, a disease specific accreditation by the Joint Commission in 
Inpatient Diabetes Care, and a team of Endocrinologists on staff. This study was supported not 
only by local leadership but by the hospital system’s clinical leadership as well. The stability 
requirement implemented in April 2015 continues to be part of the CDSS propriety algorithm 
and utilized daily by providers and clinicians.  
Results Compared to Evidence in the Literature 
There were no previously published studies in the literature specifically evaluating a 
CDSS stability requirement for the transition from intravenous to subcutaneous insulin. While 
there is large amount of literature to support the use of CDSS in the dosing of intravenous 
insulin, including two that directly site the program evaluated in this study, there is significantly 
less literature related to the transition process following CDSS dosing recommendations 
(Cochran et al., 2006; Igneri et al., 2016). Recently, the implementation of CDSS dosing 
subcutaneous insulin has been evaluated, but these programs actually modify subcutaneous doses 
during the inpatient admission and differ substantially from the one-time orders generated by the 
CDSS evaluated in this study (Neubauer et al., 2015).  
Limitations 
EFFECTS ON GLYCEMIC OUTCOMES 26 
The retrospective design of this study was the most substantial limitation. The student 
investigator attempted to reduce the impact of confounding variables on the internal validity of 
the study by evaluating factors in each cohort group that could have otherwise impacted insulin 
regimen transition and glycemic control: age, sex, type of diabetes, serum creatinine at 
admission, hemoglobin A1c, body mass index, hospital length of stay in days, hospital days with 
intravenous (IV) insulin, and presence of diabetic ketoacidosis (DKA) or hyperosmolar 
hyperglycemia syndrome (HHS). The lack of a statistically significant difference in any of the 
variables for the pre/post intervention cohorts strengthens the internal validity of the study. 
Variables not accounted for that could threaten the internal validity of the study include the use 
of medication/nutritional regimens such as vasopressors, steroids, and total parental nutrition or 
tube feedings. Additionally, this study did not capture the acuity level of the patient or diagnostic 
features outside of type of diabetes and DKA/HHS. The CDSS did undergo more updates in 
April 2015 than just the addition of the stability requirement, indicating there could be some 
imprecision in the intervention process that could threaten internal validity. The additional 
updates primarily impacted the dosing of the intravenous insulin regimen, not the transition 
process or subcutaneous dosing recommendations.  
 External validity was strengthened by including both an intensive care unit (ICU) and a 
cardiac care unit, allowing for additional generalizability outside of the ICU. The inclusion of 
adults with type 1 diabetes and those without a history of diabetes also improve the 
generalizability outside of just those with type 2 diabetes.  
Interpretation 
The expected outcome of the study indicated that by requiring patients on intravenous 
insulin to meet a stability requirement, prior to transition to subcutaneous insulin, there would be 
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an improvement in glycemic control following transition. The addition of a CDSS stability 
requirement did not result in any significant difference of the primary glycemic outcomes in 
patients transitioning from intravenous to subcutaneous insulin regimens. In addition, there was 
not a significant difference in the utilization of the CDSS transition orders between the two 
cohorts which indicated that the addition of the stability requirement did not significantly inhibit 
the provider’s use of the transition orders.  
Of interest was the significant difference in mean A1c for individuals in which the 
provider chose to utilize the CDSS transition orders in the provider discretion cohort. This 
difference was not apparent in the stability requirement cohort which indicated to the student 
investigator that providers were more likely to utilize the transition orders in the provider 
discretion cohort for individuals with poorer pre-hospital diabetes control (higher A1c), and less 
likely to use the transition orders in individuals with better pre-hospital diabetes control. The 
addition of the stability requirement may have contributed to removing this variance in use of the 
transition orders. The concern expressed by clinicians that the addition of the stability 
requirement might increase hospital length of stay or time required on intravenous insulin had no 
significant difference in hospital length of stay or days on intravenous insulin between the two 
cohorts. 
As the use of CDSS has increased in the hospital setting, software updates have become 
more commonplace. Sometimes, these updates occur entirely in the background such as updates 
to a proprietary algorithm that have not been readily apparent to frontline clinicians. Other 
updates have been much more apparent and have had an impact on the day-to-day practice of the 
clinicians. The clinical effectiveness of these updates is often unknown at the time of the update. 
The implementation of the stability requirement was based on recommendations that transition 
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off of intravenous insulin should occur when blood glucose variability was low and average 
blood glucose level was within goal range (Kreider & Lien, 2015). While this explanation, in 
theory, would provide a benefit including improved glycemic control post-transition, this study 
indicated that there was not a significant improvement. Moreover, the time of transition was no 
longer under the provider’s complete discretion, but rather had to rely on the patient meeting the 
criteria for stability. Lack of effectiveness could have been partially related to the fact that the 
site facility had an actively engaged Endocrinology service during the entire time of the data 
collection. This program may have been more effective in a facility that did not have a robust 
inpatient glycemic management service, or if patients were often being transitioned 
inappropriately. A weakness noted by the implementation team was that the term ‘stability 
requirement’ could infer stability of the patient’s medical status, which was not the case. The 
stability requirement only evaluated the stability of the patients’ blood glucose level. Even with 
the stability requirement, the decision to transition still required provider discretion regarding the 
medical acuity of the patient and whether or not transition was indicated. The student 
investigator’s assessment of the stability requirement was that it may help to prevent 
inappropriate transitions but does not necessarily lend to improved outcomes if safe practices 
around intravenous insulin transition were already in place.  
 Lastly, the results of this study implore the question of whether the burden of 
effectiveness should be on the program creators or the implementation sites. Community 
hospitals may not have the infrastructure or resources available to evaluate these program 
updates, and while analytic programs for CDSS may have been available, they only analyzed 
data while the patient was on the CDSS. Thus, there was not data available to the site facility 
from the program’s analytics for patients after they transitioned off the CDSS. Rather, the data 
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had to be manually abstracted which is a time-consuming process that may not always be 
feasible when considering the number and rate at which program updates can occur. The 600 
hours required for study design, data collection, data analysis, and dissemination were donated 
by the student investigator for the purpose of this DNP project, but considering the median 
annual salary of $97,450 for a 2000 hour work year in the state of Kansas for an advanced-
practice nurse, this project would have cost $29,235 in worked hours alone (United States 
Department of Labor, 2016).  
Conclusion 
Considering that diabetes mellitus has increased at almost epidemic proportions, 
currently affecting almost one in ten Americans and predicted to affect one in three Americans 
by 2050 (Centers for Disease Control and Prevention, 2014), a natural assumption is that the 
inpatient population of those with a diagnosis of diabetes will increase. Regardless of the 
admitting diagnosis, any patient with diabetes in the hospital setting requires glycemic 
management. Intravenous insulin dosing is the standard of care for critically ill individuals, thus 
transition from intravenous to subcutaneous insulin, and the subsequent challenges it entails will 
continue to be a necessary component of inpatient glycemic management. While the addition of 
a CDSS stability requirement did not impact the glycemic outcomes or process outcomes 
evaluated in this study, it would be prudent to evaluate this process in a setting that may not have 
access to specialists’ provider care or has a large variation in provider practice like an academic 
institution with annual changes to the residency staff. With the recent addition of CDSS for 
dosing of subcutaneous insulin regimens introduced to the inpatient settings, the ability to 
perform analytics will be improved and allow for real-time evaluation of glycemic outcomes. If 
the site facility should adopt a CDSS for subcutaneous insulin dosing, a proposed future study 
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could be a prospective pre-post intervention quasi-experimental design study evaluating the new 
software.  
Dissemination of these findings have been presented by the student investigator at the site 
facility’s Clinical Research and Evidence-Based Practice Council and the Glycemic Steering 
Committee with plans to present to the health’s systems Office of Clinical Effectiveness. The 
student investigator also plans to submit a manuscript for publication to the Journal of Diabetes 
Science and Technology. This study supports the ongoing evaluation and research of inpatient 
diabetes management CDSS in an effort to improve glycemic outcomes and subsequently reduce 
morbidity and mortality caused by dysglycemia in the hospital setting.  
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Appendix A 
Logic Model 
  
Inputs 
 Intervention(s)                        
Outputs 
 
Outcomes -- Impact 
 Activities Participation  Short Medium Long 
Evidence, sub-topics 
 
Connection between 
hyperglycemia and 
hypoglycemia and 
poor clinical outcomes 
 
Recommended 
standard of treatment 
for glycemic managem
ent in the acute care 
inpatient setting 
 
Barriers to obtaining 
optimal glycemic contr
ol during transition 
 
CDSS in the inpatient 
setting 
 
Major Facilitators or 
Contributors 
 
Health care system 
Hospital administrators 
Multi-hospital Task   
   Force  
 
Major Barriers or 
Challenges 
 
Lack of CDSS ability 
to analyze data after 
transition 
 
Large amount of 
manual data collection 
and time required to 
analyze post-transition 
glycemic outcomes 
 EBP intervention 
which is 
supported by the 
evidence in the 
Input column  
 
Implementation of a 
clinical decision 
support software 
stability 
requirement in the 
transition from 
intravenous to 
subcutaneous 
insulin regimen 
 
 
Major steps of the 
intervention   
 
Initiate Educational 
Initiative at pilot 
facility 
 
Schedule 
educational 
sessions for clinical 
nursing staff 
 
Schedule 
educational 
sessions for 
providers 
 
Work with IT and 
Informatics 
department to 
ensure software is 
installed and 
functioning 
 
"Go-Live" Week 
with onsite 
technical and 
clinical training 
teams 
 
Data collection 
The 
participants 
(subjects)   
Hospitalized 
diabetic 
and hyperglyce
mic adult 
patients 
 
 
Site 
 
Community 
Hospital in 
Suburbs of 
Kansas City 
 
Time Frame  
3 months pre 
and post 
intervention 
 
Consent 
Needed or 
other 
 
 
Person(s) 
collecting data 
 
Student 
investigator 
 
 
Others directly 
involved   
 (Completed as 
student)  
 
Outcome(s) to be 
measured with valid 
& reliable tool(s)  
 
Mean average 
glucose 
 
Number of patient 
days with glucose 
<40 
 
Number of patient 
days with glucose 
<70 
 
Number of patient 
days with any 
glucose >180 mg/dL 
 
Number of patient 
days with any 
glucose >300 mg/dL 
 
Statistical analysis 
to be used  
 
Cohort groups 
compared for initial 
demographic 
equality. 
Independent t-test 
used to compare 
continuous variables. 
Categorical variables 
compared using the 
Chi Square Test of 
Association.  
 
(after student 
DNP)  
 
Outcomes to 
be measured  
 
In the event 
the site facility 
adopts a 
CDSS for SQ 
dosing, would 
like evaluate 
glycemic 
outcomes 
before and 
after 
intervention 
 
 
 
 
 
 
 
 
(after student 
DNP) 
 
Outcomes that 
are potentials: 
 
Improved 
morbidity/mortalit
y related to 
glycemic 
outcomes 
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Appendix B 
Review of Evidence 
First author, 
Year, Title 
 
Purpose Research 
Design, 
Evidence 
Level 
Sample & 
Sampling, 
Setting 
Measur
es & 
Reliabil
ity  
Results & 
Analysis Used 
Limitations & 
Usefulness 
Dysglycemia and the Effects on Clinical Outcomes 
Center for 
Disease Control 
and Prevention 
(2014).   
National diabetes 
statistics report: 
Estimates of 
diabetes and its 
burden in the 
United States, 
2014 
This 
document is 
intended to 
provide up-
to-date 
scientific 
data and 
statistics on 
diabetes and 
its burden in 
the United 
States.  
 
Report 
published 
by the U.S. 
Departmen
t of Health 
and Human 
Services  
Level 7 
   Realistic use, 
Statistics that 
support the 
burden of 
diabetes in the 
US  
Prieto-Sanchez 
(2011). 
Hyperglycemia 
in-hospital 
management.  
 
To review 
the updated 
guidelines 
regarding IP 
glycemic 
management 
and the 
negative 
impacts of 
hyper/hypog
lycemia on 
pt outcomes 
Editorial 
Level 7 
NA Low 
Level 
This editorial 
presents the 
pathology of 
hyper/hypoglycem
ia in the inpatient 
setting in a 
concise manner 
with supporting 
evidence. 
Limited 
usefulness due to 
low level of 
evidence, 
provides good 
background 
information 
Curkendall 
(2009). 
Economic and 
Clinical Impact 
of Inpatient 
Diabetic 
Hypoglycemia.  
To assess 
the clinical 
and 
economic 
impact of 
hypoglycem
ia that 
develops 
during 
hospitalizati
on 
Retrospecti
ve cohort 
study 
Level 4 
Data from 
70 
hospitals 
was used 
to 
compare 
those 
patients 
that 
developed 
hypoglyce
mia to 
those 
whose 
blood 
glucose 
values 
were 
all >70. 
P <.01 Pts who 
developed 
hypoglycemia had 
higher charges 
(38.9%), longer 
lengths of stay 
(3.0 days), higher 
mortality, and 
higher odds of 
being discharged 
to a skilled 
nursing facility. 
 
 
Large sample, 
lower level of 
data, realistic use 
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ACE/ADA Task 
Force on 
Inpatient 
Diabetes (2006). 
ACE and ADA 
Consensus 
Statement on 
Inpatient 
Diabetes and 
Glycemic 
Control. 
Identify 
strategies to 
overcome 
barriers and 
facilitate 
improvemen
t in inpatient 
diabetes care 
Report 
from a 
Joint Task 
Force: 
Level 7 
   Sheds light on 
the progression 
of inpatient 
diabetes 
management a 
decade ago; 
background 
information  
Baker (2006). 
Hyperglycemia 
is associated 
with poor 
outcomes in 
patients admitted 
to hospital with 
acute 
exacerbations of 
chronic 
obstructive 
pulmonary 
disease.  
To 
determine 
the 
relationship 
between 
blood 
glucose 
concentratio
ns, length of 
stay in 
hospital, and 
mortality in 
patients 
admitted 
with 
AECOPD. 
Non-
experiment
al, 
Retrospecti
ve, 
correlation; 
Level 4 
433 
admission
s were 
identified, 
participant
s were 
divided 
into 4 
groups by 
blood 
glucose 
quartiles 
95% CI 
 
Relative risk of 
adverse outcomes 
was the highest in 
the group with the 
highest blood 
glucose and 
lowest in the 
lowest blood 
glucose quartile.  
Realistic use to 
show correlation 
Gandhi (2005). 
Intraoperative 
Hyperglycemia 
and perioperative 
Outcomes in 
Cardiac Surgery 
Patients. 
Estimate the 
association 
between 
intraoperativ
e 
hyperglyce
mia and 
perioperativ
e outcomes 
in pts who 
underwent 
cardiac 
surgery 
Retrospecti
ve, 
observatio
nal: Level 
4 
409 pts P<0.01 
for all 
compari
sons 
Glucose levels 
were significantly 
higher in patients 
experiencing the 
primary end point  
Older study 
significant to the 
progression of 
inpatient 
glycemic control 
over the past 10-
15 years 
Inpatient Glycemic Goals and Treatments 
American 
Diabetes 
Association 
(2016). 
Standards of 
Medical Care in 
Diabetes – 2016.  
To provide 
clinicians 
with the 
components 
of diabetes 
care, general 
treatment 
goals, and 
needed tools  
 
National 
Guidelines 
Level 1 
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Umpierrez 
(2012). 
Management of 
Hyperglycemia 
in Hospitalized 
Patients in Non-
Critical Care 
Setting: An 
Endocrine 
Society Clinical 
Practice 
Guideline.  
To provide 
practice 
guidelines 
for the 
management 
of 
hyperglyce
mia in 
hospitalized 
patients in 
the non-
critical care 
setting.  
 
Clinical 
Practice 
Guideline 
Level 1 
    
Moghissi (2009). 
American 
Association of 
Clinical 
Endocrinologists 
and American 
Diabetes 
Association 
Consensus 
Statement on 
Inpatient 
Glycemic 
Control. 
To identify 
safe 
glycemic 
targets and 
to describe 
the system 
improvemen
ts needed to 
attain them  
Clinical 
Practice 
Guidelines 
Level 1 
    
NICE-SUGAR 
Study 
Investigators 
(2009). Intensive 
versus 
Conventional 
Glucose Control 
in Critically Ill 
Patients.  
Determine 
the optimal 
blood 
glucose 
range in 
critically ill 
patients 
Large, 
internation
al 
randomize
d trail:  
Level 2 
6104 
patients 
underwent 
randomiza
tion to 
either the 
intensive 
control or 
the 
conventio
nal control 
group 
See 
next 
column. 
Severe 
hypoglycemia  
significant greater 
in the intensive 
control group -
6.8% versus 0.5% 
(P<0.001).  
Significant study 
in the 
progression of 
inpatient 
glycemic 
management 
recommendation
s and guidelines  
Griesdale (2008). 
Intensive insulin 
therapy and 
mortality among 
critically ill 
patients: a meta-
analysis 
including NICE-
SUGAR study 
data.  
To update 
the totality 
of evidence 
regarding 
the influence 
of intensive 
insulin 
therapy 
compared 
with 
conventional 
insulin 
therapy  
Meta-
analysis; 
Level 1 
    
Kosiborod 
(2008) 
Determine if 
persistent 
Retrospecti
ve, 
16, 871 
patients 
P<0.000
1 
Mean hospital 
glucose appears to 
Realistic use in 
determining 
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hyperglyce
mia has a 
greater 
impact on 
adverse 
outcomes in 
AMI than a 
single, 
random BG. 
correlation
al: Level 4 
be the most 
practical metric of 
hyperglycemia 
associate risk.  
outcome metrics 
for this project 
Van den Berghe 
(2006). Intensive 
insulin therapy in 
the Medical ICU. 
To 
determine 
whether 
intensive 
insulin 
therapy 
improves the 
prognosis of 
patients in 
the medical 
ICU 
Prospectiv,
randomize
d 
controlled 
study: 
Level 2 
1200  
patients 
p = 0.33 Intensive insulin 
therapy reduced 
blood glucose 
levels by did not 
significantly 
reduce in-hospital 
mortality.  
Intensive insulin 
therapy did 
significantly 
reduce morbidity. 
Significant study 
in the 
progression of 
inpatient 
glycemic 
management 
recommendation
s and guidelines 
Goldberg (2006). 
“Glucometrics” - 
assessing the 
quality of 
inpatient glucose 
management.  
Discuss 
standardized 
metrics for 
inpatient 
glycemic 
control 
Editorial: 
Level 7 
  The patient-day 
model appears to 
be the best 
reflection of the 
quality of 
inpatient glycemic 
control. 
Realistic use the 
determination of 
outcome metrics 
for this project. 
Garber (2004). 
American 
College of 
Endocrinology 
Position 
Statement on 
Inpatient 
Diabetes and 
metabolic 
Control 
To review 
research, 
formulate 
standards, 
and suggest 
techniques 
by which 
these goals 
may be 
achieved 
Position 
Statement; 
Clinical 
Practice 
Guidelines: 
Level 1 
   These are out-of 
date guidelines, 
but reviewed to 
establish the 
progression of 
inpatient 
management 
Van den Berghe 
(2001) 
Determine if 
normalizatio
n of blood 
glucose with 
insulin 
therapy 
improves 
prognosis 
Prospectiv
erandomiz
edcontrolle
d study: 
Level 2 
1548 pts P<0.04 Intensive insulin 
therapy reduce 
mortality for 
patients in the 
intensive care unit 
compared to 
conventional 
treatment 
Significant study 
in the 
progression of 
inpatient 
diabetes 
management 
over the last 15 - 
20 years 
Barriers to Obtaining Optimal Glycemic Control 
Draznin (2013). 
Pathways to 
Quality 
Inpatient 
Management of 
Hyperglycemia 
and 
Goal of 
promoting 
clinical 
research in 
the area of 
management 
of 
hyperglycemi
Report 
from an 
expert 
committee  
Level 7 
NA Low 
Level 
Examines the 
barriers to optimal 
diabetes 
management in 
the inpatient 
setting and 
identifies areas 
Realistic use for 
identifying 
barriers 
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Diabetes: A 
Call to  
Action.  
a and 
diabetes in 
the hospital.  
that need further 
research.  
Ross (2012). 
Inpatient 
diabetes care: 
complexity, 
resilience and 
quality of care 
To 
investigate 
how inpatient 
diabetes care 
is delivered 
and the 
implications 
for quality 
improvement. 
Qualitative 
research 
design: 
Level 6 
Non-
proportion
al quota 
sampling: 
interviewe
d 32 
diabetes 
specialists 
 
Low 
Level 
Sources of 
complexity in 
caring for 
inpatients with 
diabetes were 
identified and 
recommendations 
for coordination 
of care were made 
based on 
qualitative data 
collected. 
Realistic use for 
identifying 
barriers and 
opportunities for 
improvement in 
care coordination 
Schmeltz 
(2011). 
Management of 
Inpatient 
Hyperglycemia. 
Chief 
Endocrinolog
ist reviews 
current 
guidelines  
Editorial 
by an 
expert  
Level 7 
NA Low 
Level 
Provides practical 
insights and 
review of current 
guidelines by a 
practicing expert  
Realistic use for 
identifying 
barriers 
Braithwaite 
(2008). The 
case for 
supporting 
inpatient 
glycemic 
control 
programs now: 
The evidence 
and beyond 
To address a 
variety of 
quality and 
safety 
measures 
surrounding 
the care of 
inpatients 
with diabetes. 
Report 
from an 
expert 
committee 
Level 7 
NA Low 
Level 
Committee 
reviews the 
available evidence 
and makes 
recommendations, 
some realistic use 
in identifying 
barriers  
Realistic use for 
identifying 
barriers 
Qureshi (2012). 
Obstacles to 
Optimal 
Management of 
Inpatient 
Hyperglycemia 
in Noncritically 
Ill Patients  
To 
summarize 
obstacles in 
implementing 
standardized 
process to 
achieve 
glycemic 
goals 
Expert 
opinion 
Level 7 
NA Low 
Level 
Recommendations 
made by experts 
to give practical 
guidance to 
clinicians 
Realistic Use for 
identifying 
obstacles 
Kreider (2015). 
Transitioning 
Safely from 
Intravenous to 
Subcutaneous 
Insulin 
To suggest a 
stepwise 
approach to 
the transition 
in order to 
promote 
safety and 
euglycemia 
Expert 
opinion 
Level 7 
NA Low 
Level 
Identifies a 
significant 
opportunity for 
knowledge 
expansion in the 
area of 
transitioning from 
IV to SQ insulin 
Realistic use for 
identifying 
barriers and need 
for further 
research 
Clinical insulin dosing software programs in the inpatient setting 
 
Neubauer 
(2015).  
Standardized 
Glycemic 
Management 
with a 
To evaluate 
the safety, 
efficacy and 
usability of 
standardized 
glycemic 
Open, 
noncontroll
ed 
interventio
n study; 
99 
patients 
 
(P=0.02) 
 
Percentage of 
blood glucose 
(BG) 
measurements in 
the range of 70–
140 mg/dL, 
Realistic use 
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Computerized 
Workflow and 
Decision 
Support System 
for Hospitalized 
Patients with 
Type 2 Diabetes 
on Different 
Wards 
management 
by a CDSS 
for non-
critically ill 
hospitalized 
patients with 
DM Type 2 
Low Level 
3 
occurred in 
50.2±22.2% of 
all 
measurements. 
 
Kalfon (2014). 
Tight 
computerized 
versus 
conventional 
glucose control 
in the ICU: a 
randomized 
controlled trial. 
Assess the 
new 
generation of 
CDSSs  
Non-
blinded 
parallel-
group RCT 
trial: 
Level 2 
2,684 
patients  
 
95% CI Significant 
higher rate of 
severe 
hypoglycemia in 
the tight 
glycemic control 
group (p<0.001). 
 
 
Realistic use 
Mader (2014). 
Efficacy, 
usability and 
sequence of 
operations of a 
workflow-
integrated 
algorithm for 
basal-bolus 
insulin therapy 
in hospitalized 
type 2 diabetes 
patients. 
To evaluate 
glycemic 
control and 
usability of a 
workflow-
integrated 
algorithm for 
basal-bolus 
insulin 
therapy  
Controlled, 
non-
randomize
d Level 3 
Algorith
m based 
treatment 
was 
impleme
nted on 
one ward 
and 
compared 
to 
standard 
glycemic 
managem
ent at the 
other 
ward.  
p <0.001  Algorithm blood 
glucose levels in 
the algorithm 
group were 
significantly 
reduced and had 
a higher level of 
in-range glucose 
levels 
Realistic use, 
although this was 
a paper algorithm, 
it provides a 
similar construct 
to how a 
computerized 
algorithm would 
be utilized 
Van Herpe 
(2013). LOGIC-
Insulin 
Algorithm-
Guided Versus 
Nurse-Directed 
Blood Glucose 
Control During 
Critical Illness.  
To validate 
clinically 
LOGIC-
Insulin 
relative to 
tight 
glycemic 
control by 
experienced 
nurses. 
Prospectiv
e parallel-
group, 
randomize
d 
controlled 
clinical 
trial:  
Level 2 
300 
critically 
ill 
patients  
p<0.001 Compared to 
expert nurses, 
LOGIC-Insulin 
improved 
efficacy of tight 
glycemic control 
without 
increasing the 
rate of 
hypoglycemia.  
Validating 
algorithm for 
intravenous 
insulin dosing 
algorithm 
Mann (2011). A 
computer 
decision 
support 
software safely 
improves 
glycemic 
control in the 
burn intensive 
care unit: 
Randomized 
To determine 
the safety and 
efficacy of a 
computer 
decision 
support 
software 
(CDSS) to 
control serum 
glucose 
concentration 
in a burn 
Prospectiv
e-paired 
randomizat
ion 
crossover 
trial;  
Level 2 
18 adult 
burn/trau
ma 
patients 
 P <0.05 The patients in 
the computer 
protocol arm of 
the study spent 
47 +/- 17% of 
time in target 
range (80-110 
mg/dL) 
compared with 
41 +/- 16% of 
time for the 
Small sample 
size, one setting, 
pilot study, 
realistic use.  
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controlled 
clinical study.  
intensive care 
unit 
paper protocol 
arm 
Cochran (2006) 
EndoTool 
Software for 
Tight Glucose 
Control for 
Critically Ill 
Patients 
To evaluate 
safety and 
efficacy of 
sophisticated 
feedback 
mathematics 
applied to the 
control of a 
two variable, 
quadratic 
insulin dosing 
curve  
Retrospecti
ve, 
Observatio
nal: Level 
4 
2510 
patients, 
ICU 
patients, 
95,793 
blood 
glucose 
readings 
 Program 
provided safe 
and effective BG 
control, minimal 
hypoglycemia, 
improved 
documentation 
Limited by 
retrospective, 
observational 
nature of the 
study: specific to 
this project’s 
CDSS 
Igneri (2016) 
Evaluation of 
Glycemic 
Control with 
EndoTool 
Glucose 
Management 
System for 
Insulin Infusion 
Therapy 
To assess 
glycemic 
control in 
critically-ill 
patients 
administered 
IV insulin 
infusion with 
EndoTool 
compared to 
traditional 
protocol 
Retrospecti
ve cohort 
analysis: 
Level 4 
155 
critically 
ill 
patients 
p<0.001 Time to glycemic 
control BG <150 
was significantly 
shorter in 
EndoTool cohort, 
hypoglycemia 
episodes were 
significantly less; 
chi-square and 
Wilcoxon rank-
sum tests 
Limited by 
retrospective 
nature of the 
study; specific to 
this project’s 
CDSS 
Saur (2013) 
Software-
Guided Insulin 
Dosing: Tight 
Glycemic 
Control and 
Decreased 
Glycemic 
Derangements 
in Critically Ill 
Patients 
To determine 
if glycemic 
derangements 
are more 
effectively 
controlled 
using 
software-
guided 
insulin dosing 
compared 
with paper-
based 
protocols. 
Prospectiv
e, 
nonrandom
ized, 
before and 
after 
cohort: 
Low Level 
3 
197 
critically 
ill 
patients 
P<.001 Patients in the 
software guided 
group were dc’d 
from ICU more 
often with a 
normalized BG 
compaired to 
those on paper-
based insulin 
dosing regimen. 
Less 
hypoglycemia in 
the software-
guided cohort.  
Small sample 
size, pilot trial at a 
single institution  
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Appendix C 
Definition of Terms 
 Clinical Decision Support Software. Rule or algorithm-based software integrated with 
electronic health records and evidence-based knowledge (Moja et al., 2014). 
 Dysglycemia. Glucose levels out of normal range, hypoglycemia or hyperglycemia 
(American Diabetes Association, 2016).   
 Hypoglycemia. Any blood glucose less than 70 mg/dL (American Diabetes Association, 
2016).  
Multi-modal Insulin Regimen. A a combination of long-acting basal insulin, usually 
administered once or twice daily, and short-acting insulin administered three times daily with 
meals with the option of correctional insulin (American Diabetes Association, 2016).  
Severe Hypoglycemia. Any blood glucose less than 40 mg/dL (American Diabetes 
Association, 2016).  
  
EFFECTS ON GLYCEMIC OUTCOMES 47 
Appendix D 
Theory to Application Diagram 
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Appendix E 
IRB Approval Letter 
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Appendix F 
Data Collection Template 
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Appendix G 
Intervention Explanation 
How a CDSS doses insulin: 
  
 
Message that Appears if Patient has not met the Stability Requirement: 
 
Message that Appears if Patient has met the Stability Requirement: 
 
 
 
…is utilized by the 
software program to 
generate an 
intravenous insulin 
dosing protocol 
Data uploaded from 
the electronic 
medical record  
+ 
Data entered by the 
registered nurse… 
Transition orders are 
not accessible 
Transition orders are 
accessible 
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Examples of patients that meet and do not meet the criteria for stability: 
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Appendix H 
Project Timeline Flow Graphic 
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Appendix I 
Intervention Flow Diagram 
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Appendix J 
Statistical Analysis  
Continuous Variables Presented as Mean +/- Standard Deviation 
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Continuous Variables: Significance Tests 
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Categorical Data Presented as Numeric Counts of Percentages: Cohort by Sex 
 
 
Note. Interpretation: X21 =.396; P=.529 
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Categorical Data Presented as Numeric Counts of Percentages: Cohort by Diabetes Status 
 
 
Note. Interpretation: X22 = 2.371; P=.306 
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Categorical Data Presented as Numeric Counts of Percentages: Cohort by DKA or HHS 
 
 
Note. Interpretation: X22 = .195; P=.907 
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Day of Transition: Number of Patient Days Within Range  
 
 
Note. Interpretation: X21 = 1.451; P=.228 
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Day of Transition: Number of Patient Days with a Blood Glucose <40 mg/dL  
 
 
Note. Interpretation: X21= 2.032; P=.154 
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Day of Transition: Number of Patient Days with a Blood Glucose <70 mg/dL 
 
 
Note. Interpretation: X21 = 1.021; P=.312 
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Day of Transition: Number of Patient Days with a Blood Glucose >180 mg/dL 
 
 
 
Note. Interpretation: X21 = 1.205; P=.272 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 63 
Day of Transition: Number of Patient Days with a Blood Glucose >300 mg/dL 
 
 
Note. Interpretation: X21 = 1.951; P=.163 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 64 
Subcutaneous Insulin Regimen Day 1: Number of Patient Days Within Range 
 
 
Note. Interpretation: X21 = 2.360; P=.124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 65 
Subcutaneous Insulin Regimen Day 1: Number of Patient Days with a Blood Glucose <40 mg/dL 
 
 
 
Note. Interpretation: X21 = 1.772; P=.183 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 66 
Subcutaneous Insulin Regimen Day 1: Number of Patient Days with a Blood Glucose <70 mg/dL 
 
 
Note. Interpretation: X21 = 1.090; P = .296 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 67 
Subcutaneous Insulin Regimen Day 1: Number of Patient Days with a Blood Glucose            
>180 mg/dL 
 
 
Note. Interpretation: X21 = .319; P=.572 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 68 
Subcutaneous Insulin Regimen Day 1: Number of Patient Days with a Blood Glucose           
>300 mg/dL 
 
 
Note. Interpretation: X21 = .009; P = .924 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 69 
Subcutaneous Insulin Regimen Day 2: Number of Patient Days Within Range 
 
 
Note. Interpretation: X21 = .062; P=.803 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 70 
Subcutaneous Insulin Regimen Day 2: Number of Patient Days with a Blood Glucose <40 mg/dL 
 
 
Note. Interpretation: X21 = 2.979; P=.084 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 71 
Subcutaneous Insulin Regimen Day 2: Number of Patient Days with a Blood Glucose <70 mg/dL 
 
 
Note. Interpretation: X21 = 2.085; P=.149 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 72 
Subcutaneous Insulin Regimen Day 2: Number of Patient Days with a Blood Glucose           
>180 mg/dL 
 
 
 
Note. Interpretation: X21 = .007; P=.932 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 73 
Subcutaneous Insulin Regimen Day 2: Number of Patient Days with a Blood Glucose           
>300 mg/dL 
 
 
Note. Interpretation: X21 = .132; P=.716 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 74 
Subcutaneous Insulin Regimen Day 3: Number of Patient Days Within Range 
 
 
Note. Interpretation: X21 = .029; P=.865 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 75 
Subcutaneous Insulin Regimen Day 3: Number of Patient Days with a Blood Glucose <40 mg/dL 
 
 
Note. Interpretation: X21 = 4.188; P=.041 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 76 
Subcutaneous Insulin Regimen Day 3: Number of Patient Days with a Blood Glucose <70 mg/dl 
 
 
Note. Interpretation: X21 = 2.119; P=.145 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 77 
Subcutaneous Insulin Regimen Day 3: Number of Patient Days with a Blood Glucose           
>180 mg/dl 
 
 
Note. Interpretation: X21 = .047; P=.829 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 78 
Subcutaneous Insulin Regimen Day 3: Number of Patient Days with a Blood Glucose           
>300 mg/dL   
 
 
Note. Interpretation: X21 = .053; P=.818 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 79 
Use of transition orders by provider  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 80 
Influence of Cohort Group on Hospital Length of Stay  
 
 
Note. Interpretation t(126) = .679, P = .503 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 81 
Relationship between hemoglobin A1c for individuals with or without transition orders by cohort 
group 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 82 
Interaction between Cohort and the Writing of Transition Orders when Measuring Patient Days 
with IV Insulin 
 
 
 
 
 
 
EFFECTS ON GLYCEMIC OUTCOMES 83 
Appendix K 
 
 
